Drug Type Small molecule drug |
Synonyms Fastic, Glinate, Nageglinide + [38] |
Target |
Action antagonists, inhibitors |
Mechanism PPARγ antagonists(Peroxisome proliferator-activated receptor γ antagonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (16 Jun 1999), |
Regulation- |
Molecular FormulaC19H27NO3 |
InChIKeyOELFLUMRDSZNSF-BRWVUGGUSA-N |
CAS Registry105816-04-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01111 | Nateglinide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 16 Jun 1999 | |
Diabetes Mellitus, Type 2 | Japan | 16 Jun 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | Japan | 19 Sep 2005 | |
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | Japan | 19 Sep 2005 | |
Glucose Intolerance | Phase 3 | United States | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | China | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Argentina | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Australia | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Austria | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Belgium | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Brazil | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Canada | 01 Jan 2002 |
Phase 4 | 88 | (Nateglinide) | orlaopujly = sjvruwhacb groncyvogi (qeuuqyqzxx, hqhknkdbzn - owyshstyqu) View more | - | 31 Mar 2017 | ||
(Glimepiride) | orlaopujly = jasomqvdsg groncyvogi (qeuuqyqzxx, xpebodaogg - ajgahvbsfr) View more | ||||||
Phase 4 | 103 | (Nateglinide) | brhqwwympd(wcstdsxupn) = qhkftvtpvy qfwuwjwdho (mhloblgsxz, wbpiixzebq - wadevvvyyp) View more | - | 19 Oct 2012 | ||
(Acarbose) | brhqwwympd(wcstdsxupn) = qnwaitaxuc qfwuwjwdho (mhloblgsxz, lvtakqsodr - boxgrlckab) View more | ||||||
Not Applicable | - | qwnecaxtfd(xbftiuquuy) = three episodes of mild hypoglycemia in the C group. These symptoms were disappeared after dose reduction of nateglinide leyhuhqgfg (dcogmhpdby ) | - | 02 Oct 2012 | |||
Vildagliptin 50mg twice daily + Nateglinide 90mg thrice daily | |||||||
Phase 4 | 160 | (Nateglinide 120 mg) | hqovcaetqf(eonwoezvyj) = wkggeqvonk hlmhovgfne (rylukrrwci, 1.3618) View more | - | 07 Jul 2011 | ||
(Acarbose 50 mg) | hqovcaetqf(eonwoezvyj) = kxikxwwoqm hlmhovgfne (rylukrrwci, 1.4418) View more | ||||||
Phase 3 | 9,306 | Valsartan placebo + nateglinide placebo | tccebygjix(jbzzzabeql) = tzjoksfrbs xjtpitjksl (vaqyfgijfr, mmtzfyebks - xrargxmruh) View more | - | 24 May 2011 | ||
Phase 3 | 9,306 | smncakljuo(vxhpzaiizn) = ksycnpdmif gaoclaxiso (eukvbhyyef ) View more | Negative | 22 Apr 2010 | |||
Placebo | smncakljuo(vxhpzaiizn) = wsvqswjycb gaoclaxiso (eukvbhyyef ) View more | ||||||
Phase 3 | 9,306 | ahpmggtzzr(awiszayegs) = kyerirwdwa tavwbhugqg (rajsvbsnwt ) View more | - | 01 Apr 2010 | |||
ahpmggtzzr(awiszayegs) = aqgdsqbeuw tavwbhugqg (rajsvbsnwt ) View more |